Regulatory Agios mulls early FDA filing for sickle cell therapy PharmaphorumAgios is planning to file its sickle cell disease candidate mitapivat with the FDA under the accelerated pathway within the next few months.RegulatoryHematologyRead full story pharminent April 1, 2026 (Last updated: April 1, 2026) Pharmaphorum Agios is planning to file its sickle cell disease candidate mitapivat with the FDA under the accelerated pathway within the next few months. RegulatoryHematologyRead full story Post navigation Previous: Biogen uplifts rare disease pipeline with $5.6bn Apellis buyoutNext: A ‘hijacked plane’: CDC, under RFK Jr.’s influence, trades science for dogma Related Stories Regulatory Ultragenyx wins FDA approval for first treatment targeting root cause of GSDIa pharminent August 20, 2026 Regulatory Regeneron wins FDA approval to challenge Ipsen for rare bone disease market pharminent August 20, 2026 Regulatory FDA grants accelerated approval to Ultragenyx’s Genglycos gene therapy pharminent August 20, 2026
